双鹭药业理财投资损失拖累业绩，董事长承诺“自掏腰包”弥补损失

Core Viewpoint - Double-Helix Pharmaceutical (002038) is expected to continue incurring losses in 2025, with a projected net profit loss of between -200 million to -290 million yuan, representing a year-on-year decline of 170.03% to 291.54% [3][4] Group 1: Financial Performance - The company reported a net profit loss of approximately -74.07 million yuan in 2024, marking a shift from profit to loss [3] - The expected non-recurring losses for 2025 are estimated to reduce net profit by about 200 million yuan, significantly impacting overall financial performance [5] - The sales revenue for 2024 was approximately 660 million yuan, a year-on-year decrease of 35.15% [3] Group 2: Sales and Margins - Sales gross margin decreased by about 10% due to a decline in product prices, which was influenced by centralized procurement policies [4] - The company's major product line, anti-tumor and immune regulation products, generated sales of 276 million yuan, accounting for 42.69% of total sales, with a year-on-year decline of 27.69% [4] Group 3: Investment and Financial Losses - The company faced significant investment losses, particularly from financial assets, which have become a critical factor affecting its performance [6] - Chairman Xu Mingbo has voluntarily committed to cover the irrecoverable portion of investment losses, with an initial payment of 50 million yuan to the company [5] Group 4: Strategic Response - The company plans to accelerate the launch of new products and strengthen its marketing network to adapt to changes in the pharmaceutical market due to procurement policies [5]